



February 11, 2011

Dear Doctors and Mid-level Providers,


A new protocol has been approved by the Forsyth Medical Center IRB: Vitamin D and Breast Cancer Biomarkers. Eligibility includes premenopausal women 55 years of age or younger with regular menstrual cycles (at least four cycles in the last six months) and have a breast density greater than or equal to 25 percent. Patients with scattered fibroglandular densities and heterogeneously dense breasts are appropriate patients.

Women with increased breast density will be identified by radiologists in their routine screening mammography. Information is available to patients at The Breast Clinic and they may be contacted to discuss their interest and eligibility.

The National Cancer Institute approved funding for this prospective, double-blinded, randomized placebo-controlled clinical trial for 250 pre-menopausal women with increased breast density (greater than or equal to 25% of total breast tissue). Women will be randomly assigned to receive 2,000 IU of Vitamin D or placebo daily for one year. A one year intervention will minimize unnecessary radiation from mammography and account for seasonal variation in solar Vitamin D by obtaining pre and post-study mammograms at the same time (season) of the year.

If you have questions or any comments, please contact any one of the resources below. We are excited to be able to offer this breast cancer prevention trial to the community. It is the third in a lineage (Breast Cancer Prevention Trial (BCPT), Study of Tamoxifen and Raloxifene (STAR)) that has been available with the hope that we can decrease the incidence of breast cancer in our community.

Regards,


Judith Hopkins, MD
Principal Investigator
FRCC


LeeAnn Naylor, MD
Radiologist
The Breast Clinic


Marcella Butler, MD
Radiologist
The Breast Clinic


Elizabeth White
NCI-Research
FRCC
(336) 718-8461